Press Release | NeoGenomics Laboratories

January 17, 2014

NeoGenomics Schedules its Q4 2013 and Full Year 2013 Earnings Release for February 19, 2014

January 7, 2014

NeoGenomics is the First Laboratory to Offer Calreticulin (CALR) Mutation Testing for the Diagnosis and Classification of Myeloproliferative Neoplasms

October 23, 2013

NeoGenomics Reports Record Revenue of $16.9 Million, Adjusted EBITDA of $2.2 Million and Net Income of $900K for the Third Quarter 2013

October 7, 2013

NeoGenomics Schedules its Q3 2013 Earnings Release for October 23, 2013

September 26, 2013

NeoGenomics Revises Upward its Quarter 3 2013 Guidance

April 25, 2013

NeoGenomics Reports Record Quarterly Revenue of $15.7 Million, Adjusted EBITDA of $1.8 Million and 46.3% Gross Margin for the First Quarter

April 17, 2013

NeoGenomics Schedules its Q1 2013 Earnings Release for April 25, 2013

February 28, 2013

NeoGenomics Announces Pricing of $9.5 Million Public Offering

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients